[{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"CR2O","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Rubic Consortium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic Tech Transfer and Licensing Agreement SA Rubic Consortium Aim Develop","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"$0.5 million","newsHeadline":"Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Announces Successful Toxicology Data Published in \"Toxicologic Pathology\"","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Rubic One Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Vaccine and Immunotherapy Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic\u2019s C1 Platform Selected by the Vaccine and Immunotherapy Center (\u201cVIC\u201d) at Massachusetts General Hospital as Part of VIC\u2019s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vacci","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Dyadic International, Inc
The collaboration aims to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.
The collaboration aims to support Dyadic's in microbial platforms for flexible-scale protein bioproduction and the IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats.
The collaboration aims to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform, targeting infectious and other diseases.
DYAI-100, also known as C1-SARS-CoV-2 RBD vaccine, is a novel receptor-binding domain (RBD) recombinant protein booster vaccine candidate, highly expressed in Dyadic's proprietary C1-cell protein production platform for the prevention of COVID-19.
The collaboration aims to use Dyadic’s proprietary C1 protein production platform for rapid production of prophylactic vaccines for influenza A and other infectious diseases.
DYAI-100, also known as C1-SARS-CoV-2 RBD vaccine, is a novel receptor binding domain recombinant protein booster vaccine candidate, highly expressed in dyadic's proprietary C1-cell protein production platform for the prevention of covid-19.
The Patent will cover claims for the development and manufacture of seasonal and pandemic influenza vaccines from the Company's C1 protein production platform.
The agreement aims to develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved African countries using Dyadic's C1-cell protein expression platform.
DYAI-100, also known as C1-SARS-CoV-2 RBD vaccine, is a novel receptor binding domain recombinant protein booster vaccine candidate, highly expressed in Dyadic's proprietary C1-cell protein production platform for the prevention of COVID-19.
DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine, produced using the C1 platform, administered as a booster vaccine at two single dose levels in healthy volunteers.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
